Market Overview:
The global Parkinson disease drug market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of Parkinson’s disease, rising geriatric population, and technological advancements in the field of Parkinson’s disease drugs. Based on type, the global Parkinson disease drug market is segmented into Sinemet-CR, Trastal, Madopar, COMT inhibitor and other drugs for treating Parkinson’s disease. The Sinemet-CR segment is expected to account for a major share of the global market due to its high usage rate across all age groups. Based on application, the global market is divided into three segments namely under 40 years old patients; 40-65 years old patients; and above 65 years old patients.
Product Definition:
Parkinson Disease Drug is a medication used to treat Parkinson's disease. It works by increasing the amount of dopamine in the brain. Dopamine is a chemical that helps control movement and coordination.
Sinemet-CR:
Sinemet-CR is a drug developed by Carveyor Pharma for the treatment of Parkinson's disease. It is an off-label drug used for the treatment of rigidity and slowness of movement, postucleus motorium lesions, which were previously treated with L-dopa (Levodopa).
Trastal:
Trastal is a new drug developed by the scientists at the University of Liege in Belgium to treat Parkinson's disease. The drug has been tested on more than 1,000 patients and has shown positive results. However, it needs to go through several stages before it can be approved by regulatory bodies such as FDA and EMA for usage across the globe.
Application Insights:
Based on application, the market is segmented into under 40 years old, 40-65 years old and above 65 years old. The Parkinson disease drugs are generally used in patients who have been diagnosed with PD for the treatment of symptoms such as bradykinesia, rigidity and tremor. However, high cost of these drugs coupled with low usage rates has hampered their demand in recent times.
The other category includes diseases related to Parkinson including striatonigral degeneration and parkinsonism caused by multiple system atrophy. In addition to this, there are a few other rarer forms of PD such as olivoponto-temporal syndrome (OPT) that affects around 1 per 2 million people globally each year; however due to lack of awareness about these disorders among healthcare professionals and patients; hence there is an absence of reliable data pertaining to this disorder which further hampers market growth during forecast period.
Regional Analysis:
North America dominated the global Parkinson disease drug market in 2017. The presence of key pharmaceutical companies, availability of effective treatment options, and high awareness levels regarding early diagnosis are some of the major factors responsible for this dominance. Moreover, according to recent statistics published by Parkinson’s Foundation International (PFI), around 30 million people globally were diagnosed with PD in 2016 and approximately 60 thousand new cases were reported annually from the U.S.
Asia Pacific is expected to be one of fastest-growing regions during the forecast period owing to rising healthcare expenditure levels coupled with increasing government initiatives pertaining towards tackling neurodegenerative disorders such as Parkinson's disease (PD). In addition, improving healthcare infrastructure and rising patient awareness about available treatment options will also drive growth over this period.
Growth Factors:
- Increasing incidence of Parkinson's disease (PD) due to aging population.
- Growing demand for better treatment options for PD patients.
- increasing research and development activities for new PD drugs.
- rising healthcare expenditure by governments and private players to support the treatment of PD patients .
Scope Of The Report
Report Attributes
Report Details
Report Title
Parkinson Disease Drug Market Research Report
By Type
Sinemet-CR, Trastal, Madopar, COMT Inhibitor, Other, Parkinson Disease Dru
By Application
Under 40 Years Old, 40-65 Years Old, Above 65 Years Old
By Companies
Merck, Akorn, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie, Kyowa Hakko Kirin Pharma, Astellas Pharma, Desitin Arzneimittel, Endo Pharmaceuticals, F.Hoffmann-La Roche, H.Lundbeck, Valeant, Apokyn, Orion, Stada Arzneimittel, US WorldMeds, Bausch Health, Parkinson Disease Dru
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
240
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Parkinson Disease Drug Market Report Segments:
The global Parkinson Disease Drug market is segmented on the basis of:
Types
Sinemet-CR, Trastal, Madopar, COMT Inhibitor, Other, Parkinson Disease Dru
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Under 40 Years Old, 40-65 Years Old, Above 65 Years Old
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Akorn
- GSK
- Novartis
- Boehringer Ingelheim
- Teva Pharmaceutical
- Abbvie
- Kyowa Hakko Kirin Pharma
- Astellas Pharma
- Desitin Arzneimittel
- Endo Pharmaceuticals
- F.Hoffmann-La Roche
- H.Lundbeck
- Valeant
- Apokyn
- Orion
- Stada Arzneimittel
- US WorldMeds
- Bausch Health
- Parkinson Disease Dru
Highlights of The Parkinson Disease Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Sinemet-CR
- Trastal
- Madopar
- COMT Inhibitor
- Other
- Parkinson Disease Dru
- By Application:
- Under 40 Years Old
- 40-65 Years Old
- Above 65 Years Old
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Parkinson Disease Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Parkinson Disease Drug is a medication used to treat Parkinson's disease.
Some of the major companies in the parkinson disease drug market are Merck, Akorn, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie, Kyowa Hakko Kirin Pharma, Astellas Pharma, Desitin Arzneimittel, Endo Pharmaceuticals, F.Hoffmann-La Roche, H.Lundbeck, Valeant, Apokyn, Orion, Stada Arzneimittel, US WorldMeds, Bausch Health, Parkinson Disease Dru.
The parkinson disease drug market is expected to grow at a compound annual growth rate of 7.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Parkinson Disease Drug Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Parkinson Disease Drug Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Parkinson Disease Drug Market - Supply Chain
4.5. Global Parkinson Disease Drug Market Forecast
4.5.1. Parkinson Disease Drug Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Parkinson Disease Drug Market Size (000 Units) and Y-o-Y Growth
4.5.3. Parkinson Disease Drug Market Absolute $ Opportunity
5. Global Parkinson Disease Drug Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Parkinson Disease Drug Market Size and Volume Forecast by Type
5.3.1. Sinemet-CR
5.3.2. Trastal
5.3.3. Madopar
5.3.4. COMT Inhibitor
5.3.5. Other
5.3.6. Parkinson Disease Dru
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Parkinson Disease Drug Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Parkinson Disease Drug Market Size and Volume Forecast by Application
6.3.1. Under 40 Years Old
6.3.2. 40-65 Years Old
6.3.3. Above 65 Years Old
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Parkinson Disease Drug Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Parkinson Disease Drug Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Parkinson Disease Drug Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Parkinson Disease Drug Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Parkinson Disease Drug Demand Share Forecast, 2019-2026
9. North America Parkinson Disease Drug Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Parkinson Disease Drug Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Parkinson Disease Drug Market Size and Volume Forecast by Application
9.4.1. Under 40 Years Old
9.4.2. 40-65 Years Old
9.4.3. Above 65 Years Old
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Parkinson Disease Drug Market Size and Volume Forecast by Type
9.7.1. Sinemet-CR
9.7.2. Trastal
9.7.3. Madopar
9.7.4. COMT Inhibitor
9.7.5. Other
9.7.6. Parkinson Disease Dru
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Parkinson Disease Drug Demand Share Forecast, 2019-2026
10. Latin America Parkinson Disease Drug Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Parkinson Disease Drug Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Parkinson Disease Drug Market Size and Volume Forecast by Application
10.4.1. Under 40 Years Old
10.4.2. 40-65 Years Old
10.4.3. Above 65 Years Old
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Parkinson Disease Drug Market Size and Volume Forecast by Type
10.7.1. Sinemet-CR
10.7.2. Trastal
10.7.3. Madopar
10.7.4. COMT Inhibitor
10.7.5. Other
10.7.6. Parkinson Disease Dru
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Parkinson Disease Drug Demand Share Forecast, 2019-2026
11. Europe Parkinson Disease Drug Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Parkinson Disease Drug Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Parkinson Disease Drug Market Size and Volume Forecast by Application
11.4.1. Under 40 Years Old
11.4.2. 40-65 Years Old
11.4.3. Above 65 Years Old
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Parkinson Disease Drug Market Size and Volume Forecast by Type
11.7.1. Sinemet-CR
11.7.2. Trastal
11.7.3. Madopar
11.7.4. COMT Inhibitor
11.7.5. Other
11.7.6. Parkinson Disease Dru
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Parkinson Disease Drug Demand Share, 2019-2026
12. Asia Pacific Parkinson Disease Drug Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Parkinson Disease Drug Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Parkinson Disease Drug Market Size and Volume Forecast by Application
12.4.1. Under 40 Years Old
12.4.2. 40-65 Years Old
12.4.3. Above 65 Years Old
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Parkinson Disease Drug Market Size and Volume Forecast by Type
12.7.1. Sinemet-CR
12.7.2. Trastal
12.7.3. Madopar
12.7.4. COMT Inhibitor
12.7.5. Other
12.7.6. Parkinson Disease Dru
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Parkinson Disease Drug Demand Share, 2019-2026
13. Middle East & Africa Parkinson Disease Drug Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Parkinson Disease Drug Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Parkinson Disease Drug Market Size and Volume Forecast by Application
13.4.1. Under 40 Years Old
13.4.2. 40-65 Years Old
13.4.3. Above 65 Years Old
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Parkinson Disease Drug Market Size and Volume Forecast by Type
13.7.1. Sinemet-CR
13.7.2. Trastal
13.7.3. Madopar
13.7.4. COMT Inhibitor
13.7.5. Other
13.7.6. Parkinson Disease Dru
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Parkinson Disease Drug Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Parkinson Disease Drug Market: Market Share Analysis
14.2. Parkinson Disease Drug Distributors and Customers
14.3. Parkinson Disease Drug Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Merck
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Akorn
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. GSK
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Novartis
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Boehringer Ingelheim
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Teva Pharmaceutical
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Abbvie
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Kyowa Hakko Kirin Pharma
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Astellas Pharma
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Desitin Arzneimittel
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Endo Pharmaceuticals
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. F.Hoffmann-La Roche
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. H.Lundbeck
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Valeant
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Apokyn
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Orion
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Stada Arzneimittel
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. US WorldMeds
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. Bausch Health
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. Parkinson Disease Dru
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
